{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:47Z","timestamp":1740108167320,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"None"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s00066-022-02022-0","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T10:02:12Z","timestamp":1669629732000},"page":"293-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma"],"prefix":"10.1007","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-0773","authenticated-orcid":false,"given":"Beno\u00eet","family":"Allignet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-8321","authenticated-orcid":false,"given":"Pierre","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-1269","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Mornex","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-8243","authenticated-orcid":false,"given":"Floriane","family":"Izarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8169-6745","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Rode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5701-3588","authenticated-orcid":false,"given":"Jean-Yves","family":"Mabrut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-0902","authenticated-orcid":false,"given":"Kayvan","family":"Mohkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"2022_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung\u00a0H, Ferlay\u00a0J, Siegel\u00a0RL, Laversanne\u00a0M, Soerjomataram\u00a0I, Jemal\u00a0A et\u00a0al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA A Cancer J Clin"},{"key":"2022_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle\u00a0PR, Forner\u00a0A, Llovet\u00a0JM, Mazzaferro\u00a0V, Piscaglia\u00a0F, Raoul\u00a0JL et\u00a0al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J\u00a0Hepatol 69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"2022_CR3","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero\u00a0JA, Kulik\u00a0LM, Sirlin\u00a0CB, Zhu\u00a0AX, Finn\u00a0RS, Abecassis\u00a0MM et\u00a0al (2018) Diagnosis, staging, and management of Hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 68:723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913","journal-title":"Hepatology"},{"key":"2022_CR4","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S0168-8278(03)00349-0","volume":"39","author":"L Bolondi","year":"2003","unstructured":"Bolondi\u00a0L (2003) Screening for hepatocellular carcinoma in cirrhosis. J\u00a0Hepatol 39:1076\u20131084. https:\/\/doi.org\/10.1016\/S0168-8278(03)00349-0","journal-title":"J Hepatol"},{"key":"2022_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","volume":"100","author":"E Sapir","year":"2018","unstructured":"Sapir\u00a0E, Tao\u00a0Y, Schipper\u00a0MJ, Bazzi\u00a0L, Novelli\u00a0PM, Devlin\u00a0P et\u00a0al (2018) Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 100:122\u2013130. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.09.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022_CR6","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.18632\/oncotarget.20119","volume":"8","author":"H Xie","year":"2017","unstructured":"Xie\u00a0H, Yu\u00a0H, Tian\u00a0S, Yang\u00a0X, Wang\u00a0X, Yang\u00a0Z et al (2017) What is the best combination treatment with transarterial chemoembolization of unresectable hepatocellular carcinoma? A systematic review and network meta-analysis. Oncotarget 8:100508\u2013100523. https:\/\/doi.org\/10.18632\/oncotarget.20119","journal-title":"Oncotarget"},{"key":"2022_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"YR Huo","year":"2015","unstructured":"Huo\u00a0YR, Eslick\u00a0GD (2015) Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma a\u00a0systematic review and meta-analysis. JAMA Oncol 1:756\u2013765. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2189","journal-title":"JAMA Oncol"},{"key":"2022_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"SM Yoon","year":"2018","unstructured":"Yoon\u00a0SM, Ryoo\u00a0BY, Lee\u00a0SJ, Kim\u00a0JH, Shin\u00a0JH, An\u00a0JH et\u00a0al (2018) Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion : a randomized clinical trial. JAMA Oncol 4:661\u2013669. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5847","journal-title":"JAMA Oncol"},{"key":"2022_CR9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.jhep.2018.01.014","volume":"68","author":"K Mohkam","year":"2018","unstructured":"Mohkam\u00a0K, Dumont\u00a0PN, Manichon\u00a0AF, Jouvet\u00a0JC, Boussel\u00a0L, Merle\u00a0P et al (2018) No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5\u202fcm. J\u00a0Hepatol 68:1172\u20131180. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.014","journal-title":"J Hepatol"},{"key":"2022_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","volume":"13","author":"S Xu","year":"2010","unstructured":"Xu\u00a0S, Ross\u00a0C, Raebel\u00a0MA, Shetterly\u00a0S, Blanchette\u00a0C, Smith\u00a0D (2010) Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 13:273\u2013277. https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00671.x","journal-title":"Value Health"},{"key":"2022_CR11","doi-asserted-by":"publisher","first-page":"061","DOI":"10.1055\/s-0030-1247133","volume":"30","author":"A Forner","year":"2010","unstructured":"Forner\u00a0A, Reig\u00a0ME, Rodriguez de Lope\u00a0C, Bruix\u00a0J (2010) Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61\u201374. https:\/\/doi.org\/10.1055\/s-0030-1247133","journal-title":"Semin Liver Dis"},{"key":"2022_CR12","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.3390\/ijerph17093108","volume":"17","author":"X-M Mu","year":"2020","unstructured":"Mu\u00a0X\u2011M, Wang\u00a0W, Jiang\u00a0Y\u2011Y, Feng\u00a0J (2020) Patterns of comorbidity in hepatocellular carcinoma: a network perspective. Int J Environ Res Public Health 17:3108. https:\/\/doi.org\/10.3390\/ijerph17093108","journal-title":"Int J Environ Res Public Health"},{"key":"2022_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian\u00a0P, Jibara\u00a0G, Shrager\u00a0B, Schwartz\u00a0M, Roayaie\u00a0S (2015) Recurrence of hepatocellular cancer after resection. Ann Surg 261:947\u2013955. https:\/\/doi.org\/10.1097\/SLA.0000000000000710","journal-title":"Ann Surg"},{"key":"2022_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1259\/bjr\/33521596","volume":"80","author":"ZH Zhou","year":"2007","unstructured":"Zhou\u00a0ZH, Liu\u00a0LM, Chen\u00a0WW, Men\u00a0ZQ, Lin\u00a0JH, Chen\u00a0Z et al (2007) Combined therapy of transcatheter arterial chemoembolisation and three-dimensional conformal radiotherapy for hepatocellular carcinoma. Br J Radiol 80:194\u2013201. https:\/\/doi.org\/10.1259\/bjr\/33521596","journal-title":"Br J Radiol"},{"key":"2022_CR15","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1007\/s13277-015-3144-5","volume":"36","author":"C Wang","year":"2015","unstructured":"Wang\u00a0C, Li\u00a0S, Sun\u00a0A, Chen\u00a0L, Liang\u00a0R, Li\u00a0G et al (2015) The comparison of outcomes between hypofractionated and conventional 3D-CRT regimens used in combination with TACE as first-line treatment of advanced hepatocellular carcinoma. Tumor Biol 36:4967\u20134972. https:\/\/doi.org\/10.1007\/s13277-015-3144-5","journal-title":"Tumor Biol."},{"key":"2022_CR16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.radonc.2014.05.002","volume":"111","author":"S Culleton","year":"2014","unstructured":"Culleton\u00a0S, Jiang\u00a0H, Haddad\u00a0CR, Kim\u00a0J, Brierley\u00a0J, Brade\u00a0A et al (2014) Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol 111:412\u2013417. https:\/\/doi.org\/10.1016\/j.radonc.2014.05.002","journal-title":"Radiother Oncol"},{"key":"2022_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s12072-020-10088-0","volume":"14","author":"J Sun","year":"2020","unstructured":"Sun\u00a0J, Wang\u00a0Q, Hong\u00a0ZX, Li\u00a0WG, He\u00a0WP, Zhang\u00a0T et\u00a0al (2020) Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (\u2264 5\u202fcm): a\u00a0propensity score analysis. Hepatol Int 14:788\u2013797. https:\/\/doi.org\/10.1007\/s12072-020-10088-0","journal-title":"Hepatol Int"},{"key":"2022_CR18","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S51452","author":"Z Yuan","year":"2013","unstructured":"Yuan\u00a0Z, Tian\u00a0L, Pang\u00a0Q, Song\u00a0Y, Dong\u00a0Y, Zhuang\u00a0H (2013) Comparative research on the efficacy of CyberKnife\u00ae and surgical excision for Stage I hepatocellular carcinoma. Onco Targets Ther. https:\/\/doi.org\/10.2147\/OTT.S51452","journal-title":"Onco Targets Ther"},{"key":"2022_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.01157","volume":"9","author":"CL Chiang","year":"2019","unstructured":"Chiang\u00a0CL, Chan\u00a0ACY, Chiu\u00a0KWH, Kong\u00a0FM (2019) Combined stereotactic body radiotherapy and checkpoint inhibition in Unresectable Hepatocellular carcinoma: a potential synergistic treatment strategy. Front Oncol 9:1\u20139. https:\/\/doi.org\/10.3389\/fonc.2019.01157","journal-title":"Front Oncol"},{"key":"2022_CR20","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00066-018-1391-2","volume":"195","author":"CL Chiang","year":"2019","unstructured":"Chiang\u00a0CL, Chan\u00a0MKH, Yeung\u00a0CSY, Ho\u00a0CHM, Lee\u00a0FAS, Lee\u00a0VWY et al (2019) Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B\u2013C hepatocellular carcinoma. Strahlenther Onkol 195:254\u2013264. https:\/\/doi.org\/10.1007\/s00066-018-1391-2","journal-title":"Strahlenther Onkol"},{"key":"2022_CR21","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ijrobp.2019.09.006","volume":"105","author":"C Hardy-Abeloos","year":"2019","unstructured":"Hardy-Abeloos\u00a0C, Lazarev\u00a0S, Ru\u00a0M, Kim\u00a0E, Fischman\u00a0A, Moshier\u00a0E et al (2019) Safety and efficacy of liver stereotactic body radiation therapy for hepatocellular carcinoma after segmental transarterial radioembolization. Int J Radiat Oncol Biol Phys 105:968\u2013976. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.09.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022_CR22","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.ijrobp.2009.09.009","volume":"78","author":"SH Son","year":"2010","unstructured":"Son\u00a0SH, Choi\u00a0BO, Ryu\u00a0MR, Kang\u00a0YN, Jang\u00a0JS, Bae\u00a0SH et al (2010) Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys 78:1073\u20131080. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.04.011","author":"DL Andolino","year":"2011","unstructured":"Andolino\u00a0DL, Johnson\u00a0CS, Maluccio\u00a0M, Kwo\u00a0P, Tector\u00a0AJ, Zook\u00a0J et\u00a0al (2011) Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.04.011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2022_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1748-717X-7-67","volume":"7","author":"BM Barney","year":"2012","unstructured":"Barney\u00a0BM, Olivier\u00a0KR, Miller\u00a0RC, Haddock\u00a0MG (2012) Clinical outcomes and toxicity using Stereotactic Body Radiotherapy (SBRT) for advanced cholangiocarcinoma. Radiat Oncol 7:67. https:\/\/doi.org\/10.1186\/1748-717X-7-67","journal-title":"Radiat Oncol"},{"key":"2022_CR25","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold\u00a0A, Massey\u00a0CA, Kim\u00a0JJ, Brierley\u00a0J, Cho\u00a0C, Wong\u00a0RKS et\u00a0al (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J\u00a0Clin Oncol 31:1631\u20131639. https:\/\/doi.org\/10.1200\/JCO.2012.44.1659","journal-title":"J Clin Oncol"},{"key":"2022_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","volume":"126","author":"L Henke","year":"2018","unstructured":"Henke\u00a0L, Kashani\u00a0R, Robinson\u00a0C, Curcuru\u00a0A, DeWees\u00a0T, Bradley\u00a0J et al (2018) Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol 126:519\u2013526. https:\/\/doi.org\/10.1016\/j.radonc.2017.11.032","journal-title":"Radiother Oncol"},{"key":"2022_CR27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1200\/JCO.2008.20.0600","volume":"27","author":"MT Lee","year":"2009","unstructured":"Lee\u00a0MT, Kim\u00a0JJ, Dinniwell\u00a0R, Brierley\u00a0J, Lockwood\u00a0G, Wong\u00a0R et\u00a0al (2009) Phase I study of individualized stereotactic body radiotherapy of liver metastases. J\u00a0Clin Oncol 27:1585\u20131591. https:\/\/doi.org\/10.1200\/JCO.2008.20.0600","journal-title":"J Clin Oncol"},{"key":"2022_CR28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3346\/jkms.2013.28.2.213","volume":"28","author":"SH Bae","year":"2013","unstructured":"Bae\u00a0SH, Kim\u00a0M\u2011S, Cho\u00a0CK, Kim\u00a0KB, Lee\u00a0DH, Han\u00a0CJ et al (2013) Feasibility and efficacy of stereotactic ablative radiotherapy for barcelona clinic liver cancer\u2011C stage hepatocellular carcinoma. J\u00a0Korean Med Sci 28:213. https:\/\/doi.org\/10.3346\/jkms.2013.28.2.213","journal-title":"J Korean Med Sci"},{"key":"2022_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/815105","volume":"2013","author":"Y Maor","year":"2013","unstructured":"Maor\u00a0Y, Malnick\u00a0S (2013) Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol 2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/815105","journal-title":"Int J Hepatol"},{"key":"2022_CR30","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00432-015-1974-6","volume":"141","author":"JM Straub","year":"2015","unstructured":"Straub\u00a0JM, New\u00a0J, Hamilton\u00a0CD, Lominska\u00a0C, Shnayder\u00a0Y, Thomas\u00a0SM (2015) Radiation-induced fibrosis: mechanisms and implications for therapy. J\u00a0Cancer Res Clin Oncol 141:1985\u20131994. https:\/\/doi.org\/10.1007\/s00432-015-1974-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"2022_CR31","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2217\/fon-2016-0083","volume":"12","author":"K Mohkam","year":"2016","unstructured":"Mohkam\u00a0K, Golse\u00a0N, Bonal\u00a0M, Ledochowski\u00a0S, Rode\u00a0A, Selmaji\u00a0IE et\u00a0al (2016) Conformal radiotherapy as a\u00a0bridge to liver transplantation for hepatocellular carcinoma: is it safe? Future Oncol 12:1577\u20131586. https:\/\/doi.org\/10.2217\/fon-2016-0083","journal-title":"Future Oncol"},{"key":"2022_CR32","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.2217\/fon-2019-0127","volume":"15","author":"M Mourad","year":"2019","unstructured":"Mourad\u00a0M, Mabrut\u00a0J\u2011Y, Chellakhi\u00a0M, Lesurtel\u00a0M, Prevost\u00a0C, Ducerf\u00a0C et al (2019) Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a\u00a0propensity score matched analysis of postoperative morbidity and oncological results. Future Oncol 15:2517\u20132530. https:\/\/doi.org\/10.2217\/fon-2019-0127","journal-title":"Future Oncol"},{"key":"2022_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet\u00a0JM, Ricci\u00a0S, Mazzaferro\u00a0V, Hilgard\u00a0P, Gane\u00a0E, Blanc\u00a0J\u2011F et al (2008) Sorafenib in advanced hepatocellular carcinoma. N\u00a0Engl J Med 359:378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"key":"2022_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-81176-w","volume":"11","author":"SS Chu","year":"2021","unstructured":"Chu\u00a0SS, Kuo\u00a0YH, Liu\u00a0WS, Wang\u00a0SC, Ho\u00a0CH, Chen\u00a0YC et al (2021) Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a\u00a0nationwide cancer-registry-based study. Sci Rep 11:1\u20138. https:\/\/doi.org\/10.1038\/s41598-021-81176-w","journal-title":"Sci Rep"},{"key":"2022_CR35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn\u00a0RS, Qin\u00a0S, Ikeda\u00a0M, Galle\u00a0PR, Ducreux\u00a0M, Kim\u00a0T\u2011Y et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N\u00a0Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"2022_CR36","doi-asserted-by":"publisher","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su\u00a0D, Wu\u00a0B, Shi\u00a0L (2021) Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open 4:e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037","journal-title":"JAMA Netw Open"},{"key":"2022_CR37","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000515302","volume":"10","author":"A Vogel","year":"2021","unstructured":"Vogel\u00a0A, Rimassa\u00a0L, Sun\u00a0H\u2011C, Abou-Alfa\u00a0GK, El-Khoueiry\u00a0A, Pinato\u00a0DJ et al (2021) Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta-analysis. Liver Cancer 10:240\u2013248. https:\/\/doi.org\/10.1159\/000515302","journal-title":"Liver Cancer"},{"key":"2022_CR38","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem\u00a0R, Johnson\u00a0GE, Kim\u00a0E, Riaz\u00a0A, Bishay\u00a0V, Boucher\u00a0E et al (2021) Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology 74:2342\u20132352. https:\/\/doi.org\/10.1002\/hep.31819","journal-title":"Hepatology"},{"key":"2022_CR39","doi-asserted-by":"publisher","first-page":"7895","DOI":"10.3748\/wjg.v21.i25.7895","volume":"21","author":"Q Pang","year":"2015","unstructured":"Pang\u00a0Q, Qu\u00a0K, Bi\u00a0J\u2011B, Liu\u00a0S\u2011S, Zhang\u00a0J\u2011Y, Song\u00a0S\u2011D et al (2015) Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: systematic review and meta-analysis. WJG 21:7895. https:\/\/doi.org\/10.3748\/wjg.v21.i25.7895","journal-title":"WJG"},{"key":"2022_CR40","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/apt.13485","volume":"43","author":"L Bucci","year":"2016","unstructured":"Bucci\u00a0L, Garuti\u00a0F, Camelli\u00a0V, Lenzi\u00a0B, Farinati\u00a0F, Giannini\u00a0EG et al (2016) Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome. Aliment Pharmacol Ther 43:385\u2013399. https:\/\/doi.org\/10.1111\/apt.13485","journal-title":"Aliment Pharmacol Ther"},{"key":"2022_CR41","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/cncr.31215","volume":"124","author":"CE Costentin","year":"2018","unstructured":"Costentin\u00a0CE, Mourad\u00a0A, Lahmek\u00a0P, Causse\u00a0X, Pariente\u00a0A, Hag\u00e8ge\u00a0H et\u00a0al (2018) Hepatocellular carcinoma is diagnosed at a\u00a0later stage in alcoholic patients: Results of a\u00a0prospective, nationwide study. Cancer 124:1964\u20131972. https:\/\/doi.org\/10.1002\/cncr.31215","journal-title":"Cancer"},{"key":"2022_CR42","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000343840","volume":"1","author":"K Sch\u00fctte","year":"2012","unstructured":"Sch\u00fctte\u00a0K, Bornschein\u00a0J, Kahl\u00a0S, Seidensticker\u00a0R, Arend\u00a0J, Ricke\u00a0J et\u00a0al (2012) Delayed Diagnosis of HCC with Chronic Alcoholic Liver Disease. Liver Cancer 1:257\u2013266. https:\/\/doi.org\/10.1159\/000343840","journal-title":"Liver Cancer"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-02022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-022-02022-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-022-02022-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T18:38:50Z","timestamp":1676659130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-022-02022-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2022"],"URL":"https:\/\/doi.org\/10.1007\/s00066-022-02022-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"25 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.\u00a0Allignet, P.\u00a0Pradat, F.\u00a0Mornex, F.\u00a0Izarn, A.\u00a0Rode, J.-Y.\u00a0Mabrut, K.\u00a0Mohkam, and P.\u00a0Merle declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was reviewed and approved by the institutional local ethics committee, approval number 20_249. The study was performed in accordance with the 1975 Helsinki declaration and registered in clinicaltrials.gov (NCT04823715).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}